Axsome Therapeutics Stock News

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shopify and Axsome Therapeutics have crushed the market in the past five years. Thanks to a recent strategic move, Shopify's top and bottom lines should improve.

While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their earnings calls, the reality is that the

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system

Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates.

Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the

AbbVie's recent major patent cliff won't kill its returns throughout the next decade. Axsome Therapeutics is gaining in prominence thanks to an exciting late-stage pipeline.

Axsome Therapeutics has consistently beaten revenue estimates since the approval of Auvelity, indicating better-than-expected performance. While the company's expenses, particularly in commercial acti

There are several paths to millionaire status, and investing is one of them. But to give yourself a chance to become a millionaire this way, it's important to buy a diverse basket of solid companies a

AbbVie looks like a bargain that has stronger growth on the way. Axsome Therapeutics is in the early innings of what could be an exciting growth story.

Axsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat estimates. The company's shares declined post earnings announcement.

It's the dream of every investor to uncover stocks with the potential to grow tenfold within a short span. While it may sound like a lofty goal, the article reveals that it's not just a pipe dream.

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axsome Therapeutics' Auvelity is experiencing strong sales growth in the Major Depressive Disorder space, with sales of $27.6 million in the last quarter. Auvelity offers rapid onset of symptom improv